Q1 EPS Estimate for Solid Biosciences Increased by Analyst

Solid Biosciences Inc. (NASDAQ:SLDB) – Equities research analysts at Wedbush lifted their Q1 2025 earnings per share estimates for Solid Biosciences in a research note issued on Wednesday, February 19th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($0.60) per share for the quarter, up from their prior forecast of ($0.77). Wedbush currently has a “Strong-Buy” rating on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. Wedbush also issued estimates for Solid Biosciences’ Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($1.78) EPS, FY2027 earnings at ($1.79) EPS, FY2028 earnings at ($1.41) EPS and FY2029 earnings at ($0.55) EPS.

Several other research analysts have also recently commented on SLDB. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Solid Biosciences in a research note on Friday, January 10th. JPMorgan Chase & Co. lowered their price objective on Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. Chardan Capital upped their target price on Solid Biosciences from $15.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday. JMP Securities began coverage on Solid Biosciences in a report on Tuesday, December 10th. They set an “outperform” rating and a $15.00 target price for the company. Finally, Truist Financial started coverage on Solid Biosciences in a report on Wednesday, January 8th. They issued a “buy” rating and a $16.00 price objective for the company. Nine equities research analysts have rated the stock with a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Solid Biosciences presently has a consensus rating of “Buy” and an average target price of $15.40.

Solid Biosciences Price Performance

Shares of SLDB opened at $5.78 on Friday. The stock’s 50-day moving average is $3.83 and its two-hundred day moving average is $5.76. The stock has a market cap of $234.55 million, a PE ratio of -1.90 and a beta of 2.01. Solid Biosciences has a 12 month low of $2.88 and a 12 month high of $15.05.

Insider Activity

In other news, COO David T. Howton sold 5,072 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $28,403.20. Following the transaction, the chief operating officer now directly owns 15,663 shares of the company’s stock, valued at approximately $87,712.80. This represents a 24.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jessie Hanrahan sold 4,610 shares of the company’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total transaction of $25,816.00. Following the completion of the transaction, the insider now directly owns 14,235 shares in the company, valued at $79,716. This trade represents a 24.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 26,069 shares of company stock worth $137,301. Insiders own 13.63% of the company’s stock.

Hedge Funds Weigh In On Solid Biosciences

Hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. acquired a new position in shares of Solid Biosciences in the fourth quarter worth $34,000. The Manufacturers Life Insurance Company acquired a new position in shares of Solid Biosciences in the third quarter worth $71,000. Corton Capital Inc. acquired a new position in shares of Solid Biosciences in the fourth quarter worth $41,000. Invesco Ltd. acquired a new position in shares of Solid Biosciences in the fourth quarter worth $49,000. Finally, Sei Investments Co. acquired a new position in Solid Biosciences during the fourth quarter worth $52,000. 81.46% of the stock is owned by institutional investors and hedge funds.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.